Novel Agents, T-VEC Combos Mark Next Phase of Oncolytic Immunotherapy Era in Melanoma

Barbara Boughton
Published: Friday, Nov 20, 2015

“Agents such as CVA21 have the potential to induce responses in injected and non-injected lesions and to induce an overall immune response that could affect even metastatic lesions,” Andtbacka noted. “Since they can increase T-cell infiltration into tumors, oncolytic immunotherapies could be used as a rescue strategy to reconstitute the tumor microenvironment in patients resistant to checkpoint inhibitor therapies,” he added.

<<< View more from the 2015 SMR Congress




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Melanoma: Exploring BRAF/MEK in Adjuvant and Neoadjuvant SettingsSep 28, 20191.5
Medical Crossfire®: What Does Data Tell Us About How to Optimize Checkpoint Inhibitor Strategies Across Lines of Care for Patients with Melanoma?Nov 30, 20191.5
Publication Bottom Border
Border Publication
x